Streptococcal pyrogenic exotoxins A (SpeA) and C (speC) stimulate the production of inducible nitric oxide synthase (iNOS) protein in raw 264.7 macrophages

Shock

Volumn 8, Issue 6, 1997, Pages 450-453

  Christ, Elizabeth A ^a   Meals, Elizabeth ^a   English, B Keith ^a  

^a LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ERYTHROGENIC TOXIN; EXOTOXIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE; PYROGEN; SPEA PROTEIN, STREPTOCOCCUS PYOGENES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; MACROPHAGE; MOUSE; SECRETION; STREPTOCOCCUS PYOGENES; UPREGULATION;

ANIMALS; BACTERIAL PROTEINS; CELL LINE; ENZYME INDUCTION; EXOTOXINS; GENE EXPRESSION REGULATION, BACTERIAL; MACROPHAGES; MEMBRANE PROTEINS; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PYROGENS; STREPTOCOCCUS PYOGENES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0031301669     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/00024382-199712000-00010     Document Type: Article

References (33)

1. The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: Rationale and consensus definition. J Am Med Assoc 269:390-391, 1993.
2. Stevens DL, Tanner MH, Winship J, et al: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321:1-7, 1989.
3. Stevens, DL: Invasive group A streptococcus infections. Clin Infect Dis 14:2-11, 1992.
4. Kline JB, Collins, CM: Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. Infect Immun 64:861-869, 1996.
5. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK: Streptococcus pyogenes causing toxic-shock-like syndrome and other in vasive diseases: Clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 88:2668-2672, 1991.
6. Musser JM, Nelson K, Selander RK, et al: Temporal variation in bacterial disease frequency: Molecular population genetic analysis of scarlet fever epidemics in Ottawa and in eastern Germany. J Infect Dis 167:759-762, 1993.
7. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM: Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 29:1562-1567, 1991.
8. Tyler SD, Johnson WM, Huang JC, et al: Streptococcal erythrogenic toxin genes: Detection by polymerase chain reaction and association with dis ease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol 30:3127-3131, 1992.
9. Watanabe-Ohnishi R, Low DE, McGeer A, et al: Selective depletion of V beta-bearing T-cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 171:74-84, 1995.
10. Herman A, Kappler JW, Marrack P, Pullen AM: Superantigens: Mecha nism of T-cell stimulation and role in immune responses. Annu Rev Immunol 9:745-772, 1991.
11. Giroir B: Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 21:780-789, 1993.
12. Beutler B, Cerami A: The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 7:625-655, 1989.
13. Nathan C, Xie Q: Nitric oxide synthase: Roles, tolls, and controls. Cell 78:915-918, 1994.
14. Schmidt HH, Walter U: NO at work. Cell 78:919-925, 1994.
15. Dick GF, Dick GH: The etiology of scarlet fever. J Am Med Assoc 82:301-302, 1924.
16. Musser JM: Clinical relevance of streptococcal pyrogenic exotoxins in streptococcal toxic shock-like syndrome and other severe invasive infec tions. Pediatr Ann 21:821-828, 1992.
17. English BK, Patrick CC, Orlicek SL, McCordic R, Shenep JL: Lipotei- choic acid from viridans streptococci induces the production of tumor necrosis factor and nitric oxide by murine macrophages. J Infect Dis 174:1348-1351, 1996.
18. Orlicek SL, Meals E, English BK: Differential effects of tyrosine kinase inhibitors on tumor necrosis factor and nitric oxide production by murine macrophages. J Infect Dis 174:638-642, 1996.
19. Boyte WR, Meals E, English BK: Acquired hyporesponsiveness to bac terial lipopolysaccharide and interferon-gamma in RAW 264.7 macro phages. Shock 6:218-222, 1996.
20. Loftis LL, Meals E, English BK: Differential effects of pentoxifylline and interleukin-10 on production of tumor necrosis factor and inducible nitric oxide synthase by murine macrophages. J Infect Dis 175:1008-1011, 1997.
21. Denis M: Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium. J Leukocyte Biol 49:380-387, 1991.
22. Schoedon G, Schneemann M, Walter R, Blau N, Hofer S, Schaffner A: Nitric oxide and infection: Another view. Clin Infect Dis 21(Suppl 2): 5152-5157, 1995.
23. Murray HW, Teitelbaum RF: L-arginine-dependent reactive nitrogen in termediates and the antimicrobial effect fo activated human mononuclear phagocytes. J Infect Dis 165:513-517, 1992.
24. Schneeman M, Schoedon G, Hofer S, Blau N, Guerrero L, Schaffer A: Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 167:1358-1363, 1993.
25. Albina JE: On the expression of nitric oxide synthase by human macrophages: Why no NO? J Leukocyte Biol 58: 643-649, 1995.
26. Nicholson S, Bonecini-Almeida MG, Silva JRL, et al: Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 183:2293-2303, 1996.
27. Anstey NM, Weinberg JB, Hassanali MY, et al: Nitric oxide in Tanzanian children with malaria: Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 184:557-567, 1996.
28. del Pozo V, de Arruda-Chaves E, de Andres B, et al: Eosinophils tran scribe and translate messenger RNA for inducible nitric oxide synthase. J Immunol 158:859-864, 1997.
29. Fast DJ, Schlievert PM, Nelson RD: Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 57:291-294, 1989.
30. Muller-Alouf, H, Alouf JE, Gerlach D, Fitting C, Cavaillon JM: Cytokine production by murine cells activated by erythrogenic toxin type A super antigen of Streptococcus pyogenes. Immunobiology 186:435-448, 1992.
31. Muller-Alouf H, Alouf JE, Gerlach D, Ozegowski JH, Fitting C, Cavaillon JM: Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. In fect Immun 62:4915-4921, 1994.
32. Norrby-Teglund A, Norgren M, Holm SE, Andersson U, Andersson J: Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. Infect Immun 62:3731-3738, 1994.
33. Booke M, Meyer J, Lingnau W, Hinder F, Traber, LD, Traber, DL: Use of nitric oxide synthase inhibitors in animal models of sepsis. New Horiz 3:123-138, 1995.